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Abstract
Background and Objectives
Co-trimoxazole prophylaxis, currently recommended in HIV-exposed, uninfected (HEU)
children as protection against opportunistic infections, also has some anti-malarial efficacy.
We determined whether daily co-trimoxazole prophylaxis affects the natural development of
antibody-mediated immunity to blood-stage Plasmodium falciparummalaria infection.
Methods
Using an enzyme-linked immunosorbent assay, we measured antibodies to 8Plasmodium
falciparum antigens (AMA-1, MSP-119, MSP-3, PfSE, EBA-175RII, GLURP R0, GLURP R2
and CSP) in serum samples from 33 HEU children and 31 HIV-unexposed, uninfected
(HUU) children, collected at 6, 12 and 18 months of age.
Results
Compared to HIV-uninfected children, HEU children had significantly lower levels of specific
IgG against AMA-1 at 6 months (p = 0.001), MSP-119 at 12 months (p = 0.041) and PfSE at
6 months (p = 0.038), 12 months (p = 0.0012) and 18 months (p = 0.0097). No differences
in the IgG antibody responses against the rest of the antigens were observed between the
two groups at all time points. The breadth of specificity of IgG response was reduced in
HEU children compared to HUU children during the follow up period.
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Conclusions
Co-trimoxazole prophylaxis seems to reduce IgG antibody responses to P. falciparum
blood stage antigens, which could be as a result of a reduction in exposure of those children
under this regime. Although antibody responses were regarded as markers of exposure in
this study, further studies are required to establish whether these responses are correlated
in any way to clinical immunity to malaria.
Introduction
Plasmodium falciparummalaria infection is still one of the main causes of under-five child
morbidity and mortality in Sub-Saharan Africa [1]. In 2010, the World Health Organisation
(WHO) estimated that there were approximately 216 million episodes of malaria worldwide
with 174 million cases occurring in sub Saharan Africa, which resulted in over 660,000 deaths
mainly in children under-five [2]. Several factors are thought to be responsible for this high
mortality rate [3], with the host immune response to the infection playing a crucial role [4].The
immune response mechanisms are both antibody and cell mediated [5].
Passive transfer studies from adults who are immune to malaria have shown that naturally
acquired antibodies to P. falciparum are protective against malaria infection [6,7]. In children,
whilst immunity against the severe clinical symptoms may be achieved quite early in life [8],
immunity to parasite multiplication and growth develops slowly and is dependent on repeated
exposure to malaria infections over several years [9]. Exposure to P. falciparum antigens in
children is therefore essential for the acquisition of an effective antibody immune response and
substantial disruption of this exposure may delay the development of this humoral immunity
against malaria. Antibodies are surrogates of exposure to P. falciparum and henceforth acquisi-
tion of effective immune responses [10]. Antibodies directed against various parasite proteins
are thought to have a strong inhibitory effect on parasite invasion of red blood cells [10,11].
Naturally acquired IgG responses to several of the P. falciparum antigens have been shown to
be associated with reduced incidence of malaria [12–15].
Co-trimoxazole (CTX), due to its antibiotic efficacy, is recommended for prophylactic treat-
ment in HIV-infected children having been proven to reduce child mortality and morbidity in
this group [16–19]. Similarly, for HIV-exposed but not infected (HEU) children (children born
to mothers living with HIV) CTX prophylaxis is recommended from 6 weeks of age until the
age at which HIV infection is ruled out and breastfeeding is stopped [19]. Besides having po-
tent antibiotic properties, CTX is also known to be an effective anti-malarial drug [20,21]. Pre-
vious studies on malaria chemoprophylaxis using drugs primarily meant to treat malaria have
shown that continuous provision of such prophylaxis to young children impairs the develop-
ment of the host’s natural immunity against malaria thereby increasing the child’s susceptibili-
ty to malaria when the intervention is stopped [22–24]. Although CTX is not prescribed to
HEU children as a malaria chemoprophylaxis, its anti-malarial effects could have a similar ef-
fect on the development of natural immunity.
We conducted this study to investigate the effects of daily CTX prophylaxis on the magni-
tude and breadth of IgG antibody responses against P. falciparum blood stage antigens in HEU
children. With the assumption that P. falciparum transmission is heterogeneous even within
small geographical areas [25], HIV-unexposed uninfected (HUU) children from the same com-
munities of HEU children were recruited as controls.
Co-Trimoxazole Prophylaxis Effect on Malaria Immunity in HIV Exposed
PLOS ONE | DOI:10.1371/journal.pone.0121643 March 25, 2015 2 / 16
087547/Z/08/Z), the Department for International
Development (DfID) under the Development
Partnerships in Higher Education (DelPHE), the
Carnegie Corporation of New York (Grant No: B
8606), the Ford Foundation (Grant No: 1100-0399),
Google.org (Grant No: 191994), Sida (Grant No:
54100029) and the Bill and Melinda Gates
Foundation (Grant No: 51228). The funders had no
role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
Materials and Methods
Study site, participants and design
The study was conducted in Zomba district, in the southern region of Malawi. P. falciparum
malaria transmission is stable in this district with an increase in infections during the rainy sea-
son from November to April. We recruited HEU children and HUU children from 6 months
of age and followed them up until they were 18 months old.
HEU children who had confirmed PCR negative resultswere randomly selected from the
ART clinic at the Zomba central hospital. The children received daily CTX prophylaxis begin-
ning at 6 weeks of age until at 12 months of age where we conducted a rapid test to rule out
HIV infection and the mothers were asked to stop breastfeeding. The children were eligible for
inclusion if there were otherwise healthy, breastfeeding, not under any medication and if the
mothers indicated their intention to reside in the catchment area for the duration of the study.
Children were seen every six months and at each visit, 1 ml of venous blood was collected in
clot activator tubes, serum separated and stored at -80°C for serological analyses. A further1 ml
of venous blood was collected in EDTA tubes for full blood counts. Participants were defined
as having uncomplicated malaria when they were febrile at the time of recruitment or a re-
ported history of fever in the past 48 hours or had a positive Rapid Diagnostic Test (RDT) or
positive malaria thick and thin slides but had a Blantyre Coma Score of 5 and a haemoglobin
concentration above 5g/dL. Asymptomatic carriers of P. falciparum were defined as thick
blood smear negative but RT PCR positive. The study was reviewed and approved by the Col-
lege of Medicine Research Ethics Committee (COMREC) (P.05/10/954). Individual written in-
formed consent was obtained from the parents or guardians of all the children who
participated in the study.
Detection of P. falciparum parasites
Presence of P. falciparum parasites from the peripheral blood of the children during follow up
was detected by conventional microscopy and real-time PCR from blood smears and dried
blood spots respectively. Briefly, Giemsa-stained thick blood films were prepared and two-ex-
perienced microscopists interpreted each slide. Thick smears were deemed negative if 200 high
power fields were absent of any P. falciparum asexual parasites.
Two dried blood spots on Whatman FTA filter paper (WhatmanPlc, Maidstone, UK) were
cut from each filter paper by sterilized scissors and placed into 1.5ml tubes per sample. Geno-
mic DNA was then extracted from the blood spots using QIAamp DNAMini Kit protocol for
isolation of DNA from dried blood spot (Qiagen, Germany). Genomic DNA samples were am-
plified in an assay targeting the P. falciparum lactate dehydrogenase gene (Pfldh) as previously
described [26]. All reactions were run in duplicate on Applied Biosystems HT7900 Real-Time
system (AppliedBiosystems, Foster City, CA, USA). Each reaction plate included P. falciparum
strain 3D7 genomic DNA extracted from lab-cultured parasites as positive controls and a nega-
tive control with molecular-grade water, all in duplicate. For each plate, threshold lines were
set manually and mean Ct was calculated for each amplified duplicate. Samples were consid-
ered P. falciparum positive if at least one amplification curve reached the threshold line.
Recombinant proteins
The recombinant proteins were prepared and provided by Dr K. Tetteh (AMA-1, MSP-119 and
PfSE), Drs A. Mo and I. Hall (EBA-175RII), Dr D. Narum (MSP-3), Gennova, India (CSP) and
Dr M. Thiesen (GLURP R0 and R2). Apical membrane antigen 1 (AMA-1) [27], merozoite
surface protein 1–19 (MSP-119) [28], erythrocyte binding antigen 175 Region II (EBA175RII)
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[29], Merozoite surface protein 3 (MSP-3) [30], circumsporozoite protein (CSP) (Gennova,
Pune, India) [31], glutamate-rich protein fragment (GLURP-R0), GLURP-R2 [32] and P. fal-
ciparum schizonts extract (PfSE) [33].
Detection of IgG antibody levels to recombinant proteins by ELISA
IgG antibodies to each recombinant protein was assessed by ELISA as previously described
[34]. Briefly, flat bottom microtiter plates (Immulon 4HBX, Thermo scientific, USA) were
coated overnight at 4°C with malaria antigens adjusted at the following concentrations:
AMA-1 at 0.5μg/ml, MSP-119 at 0.18μg/ml, MSP-3 at 0.5μg/ml, PfSE at 1μg/ml, EBA-175RII at
0.5μg/ml, GLURP R0 at 1μg/ml, GLURP R2 at 0.25μg/ml and CSP at 1μg/ml. After wash, the
plates were blocked with 150μL of 1% skimmed milk powder in PBS/Tween (blocking buffer)
per well for three hours at room temperature. Serum samples were added after wash at 1:1000
(except for AMA-1 diluted at 1:2000) in blocking buffer and incubated overnight at 4°C.
After incubation, horseradish peroxidase-conjugated polyclonal rabbit anti-human IgG
(Dako, Glostrup, Denmark) diluted at 1:15,000 in PBS/0.05% Tween was added to each well
and incubated for three hours at room temperature. The plates were developed with TMB sub-
strate (Tebu-Bio, France) and read at 450nm with an MRX TcII reader (Dynex Technologies).
All sera were tested in duplicate. Tests were repeated if duplicate optical density (OD) values
for an individual serum sample varied by more than a factor of 1.5. Each plate included a
three-fold dilution series (1:20 to 1:4860 final dilutions) of a Tanzanian hyperimmune standard
serum pool. A titration curve was fitted to the ODs obtained for the standard serum dilutions
by least squares minimisation using a three variable sigmoid model and the solver add-in in
Excel (Microsoft), assuming an arbitrary value of 1000 Units/ml of antibody against each anti-
gen in the standard pool. OD values were converted to arbitrary units/ml (AU/ml) using this
fitted curve.
Detection of IgG antibodies to lipopolysaccharide (LPS) from Salmonella
typhimurium and Bordetella pertussis toxin (PT) by ELISA
ELISA detection of IgG to LPS from Salmonella typhimurium (STM LPS) was modified from
[35] and as described in the previous section, except ELISA plates (Immulon 4HBX, Thermo
scientific, USA) were coated overnight at 4°C using 100μL of coating buffer (1L PBS/1.59g
Na2CO3/2.93g NaHC03, pH 9.4–9.6) per well containing STM LPS (TLRgrade, Enzo Life Sci-
ences, NY, USA) adjusted at 5μg/ml. Following washing, plates were blocked with 200μL block-
ing buffer (1% skimmed milk powder in PBS) per well for one and a half hours at 37°C. Serum
samples diluted at 1:100 in sample dilution buffer (1% skimmed milk powder in PBS/Tween)
were added and incubated for 1 hour at 37°C. The protocol was completed as previously de-
scribed in the previous section.
For PT ELISA plates (Immulon 4HBX, Thermo scientific, USA) were coated overnight at
4°C with 50μl per well of PT (NIBSC, Hertfordshire, UK) in coating buffer adjusted at 200 IU/
ml. After washing, plates were blocked with 150μL blocking buffer for 1 hour at room tempera-
ture. Serum samples were diluted at 1:100 in blocking buffer and incubated for 2 hours at 37°C.
After washing, 50μL of horseradish peroxidase-conjugated polyclonal rabbit anti-human IgG
(Dako, Glostrup, Denmark) diluted at 1:15,000 in PBS/0.05% Tween was added to each well
and incubated for three hours at room temperature. Plates were processed as described in the
previous section.
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Statistical analysis
IgG antibody titers to all antigens were obtained in HEU and HUU children at different ages.
Antibody titers were logarithmically transformed following which the transformed data were
tested if they followed a normal distribution. The transformed data were observed not to follow
normal distribution and non-parametric test were used in subsequent analysis. For each anti-
gen, differences in the continuous antibody titers between groups at each time point were ana-
lyzed by a Wilcoxon rank-sum test. The anti-logged median titers plus interquartile ranges are
presented within text. We used a Wilcoxon matched pairs signed ranks test to test whether the
antibody titers to each antigen changed with time from baseline age of six months in both
groups of children. Using the normalized OD values (ELISA normalized ODs) for each malaria
antigen, a finite mixture model was used to define a cut-off value as previously described [36]
above which the antibody response was deemed positive and below negative. The prevalence of
positive antibody responses in each study group was calculated as the proportion of samples
with OD above this cut-off. The breadth of antibody responses in each group at each time
point was defined as number of positive antibody response to at least two or more antigens per
sample. Differences in the proportions of positive antibody responses between the study groups
at each time point were estimated by Chi-square and Fisher’s exact test where appropriate.
Data analysis was performed using STATA (version 12) software for Mac (StataCorp LP, Col-
lege Station, Texas, USA). Differences were considered to be statistically significant when the p
value was equal to or less than 0.05.
Results
Participant characteristics
Both the HEU and HUU groups were comparable for both baseline and follow up characteris-
tics (Table 1). The median birth weight was similar between HEU and HUU children (3.2Kgs
vs. 3Kgs, p = 0.21). All mothers of the HEU children were on ART and were taking daily CTX
prophylaxis during the entire follow up period. The number of children with asymptomatic
malaria at each scheduled visit was low in both groups, one (3%) at 6 month, 2 (6.5%) at 12
months and 2 (6.7%) at 18 months of age for HEU children and 2 (6.5%) at 6 months, none at
12 months and 2 (7.1%) at 18 months of age for HUU children. All PCR confirmed parasitae-
mic children were included in the final analysis and their IgG levels are provided in S1 Table.
The number of HEU and HUU children with at least one episode of clinical malaria at any
time of the follow up period was determined. Three (9.1%) of the HEU children had at least
one episode of clinical malaria during the follow up period compared with four (12.9%) of the
HUU children.
Gradual increase in malaria antibody responses in HEU but not HUU
following CTX prophylaxis cessation
Significant variations of antibody concentrations over time were determined in both study
groups. Antibody responses to CSP were measured to assess the level of infection to malaria an-
tigens during the follow up period in both study groups [36]. IgG antibody responses against
CSP in HEU children showed a steady increase with time observed from 6 to 12 months,
p = 0.04 and 6 to 18 months, p = 0.0018 (Fig. 1A). However, within HUU children the antibody
responses remained constant. Among HEU children, there was an increase in the IgG antibody
titres from baseline against MSP-3 from 6 to 12 months, p = 0.0463 (Fig. 1C) and against
GLURP R0 from 6 to 12 months, p = 0.0016 and 6 to 18 months, p = 0.0007 (Fig. 1D). No
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significant increase in the IgG antibody responses against the rest of the antigens over time was
observed among HUU children (Figs. 1A-1D).
However, among HEU children, there was a significant reduction in the IgG antibody titers
against EBA175RII from 6 to 18 months, p = 0.0372 (Fig. 2C) and against GLURP R2 from 6 to
18 months, p = 0.0107 (Fig. 2D). Among HUU children, there was a significant reduction in
the IgG antibody concentrations against AMA-1from 6 to 12 months, p< 0.0001 and 6 to 18
months, p = 0.0015 and against GLURP R2 from 6 to 18 months, p = 0.0021 (Fig. 2A). No sig-
nificant change from baseline in the IgG titres was observed to the remaining antigens in both
HEU and HUU children (Fig. 1 and 2).
Lower magnitude of malaria antibody titers in HEU compared to HUU
infants
The magnitude of the IgG antibody responses at the specific ages was then compared between
the study groups. HEU children had significantly low levels of IgG antibody titres to PfSE com-
pared to HUU children at 6 months (13.7AU/ml [IQR 6.0–19.6] vs. 22.9 AU/ml [IQR 8.92–
43.6] p = 0.0388), at 12 months (6.6 AU/ml [IQR 3.32–13.4] vs. 17.9 AU/ml [IQR 9.1–32.5]
p = 0.0012) and at 18 months (13.9 AU/ml [IQR 9.69–23.8] vs. 25.5 AU/ml [IQR 17.9–41.8],
p = 0.0097) (Fig. 1B). At six months of age, HEU children had significantly lower levels of IgG
antibody titers to AMA-1 compared to HUU children (5.12 AU/ml [IQR 3.06–15.09] vs.
22.1 AU/ml [IQR 7.69–56.2] p = 0.0014) (Fig. 2A) and to MSP-119 at 12 months of age com-
pared to HUU children (7.93 AU/ml [IQR 4.45–12.0] vs. 31.8 AU/ml [IQR 6.32–142.9]
p = 0.0416) (Fig. 2B). No other statistically significant differences in IgG antibody titers against
Table 1. Demographic characteristics of study participants.
Parametera Age of study participants at each visit
6 months 12 months 18 months
HUU HEU *p HUU HEU p HUU HEU p
Demographic data
Number of children at each visit 31 33 - 29 31 - 28 30 -
Females (%) 65 46 - 62 42 - 64 40 -
Physical characteristics
Weight (Kg) 8 8.3 0.37 9.2 9.5 0.33 10.1 10.8 0.33
Body temperature (°C) 36.8 36.7 0.11 36.5 36.4 0.66 36.4 36.2 0.95
MUAC (cm) 14 14 0.88 14 14 0.79 14 14 0.82
Laboratory parameters
Mean parasitaemia 1200 7820 - - - 4920 1060 -
WBC count (x103/μL) 10.2 9.45 0.51 11.5 12.0 0.65 9.5 8.4 0.34
Total B cells (%) 20.7 23.3 0.9 20.9 20.7 0.98 18.8 20.1 0.91
Haemoglobin (g/dL) 9.6 10.2 0.17 10.2 10.7 0.51 10.8 11.5 0.13
Platelets (x103/μL) 466 369 0.046 390 434 0.57 390 390 0.88
Malaria control measures
Child slept under a net (%) 86.7 93.8 - 95 95.5 - 100 100 -
If used treated net (%) 84.6 90.3 - 100 100 - 100 96.8 -
Abbreviations: P = p value, MUAC = mid upper arm circumference, WBC = white blood cells
a Presented as medians
*P value obtained with Mann-Whitney U test, p value of <0.05 was considered signiﬁcant
doi:10.1371/journal.pone.0121643.t001
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the rest of the antigens were observed between HEU and HUU children (Fig. 1 and 2). These
results suggest that the magnitude of malaria antibody titers is lower in HEU infants possibly
due to lower exposure to malaria due to the effect of CTX prophylaxis or due to HIV induced
impairment of antibody immunity.
Non-malaria antigen antibody responses are maintained over time
To measure the potential confounding effect of in-utero exposure to HIV, we measured IgG re-
sponses to STM LPS and PT in HEU children and compared with IgG responses from HUU
children. The IgG antibody titers against STM LPS were comparable between the study groups
all time points (Fig. 3A). However, HEU children had significantly higher levels IgG antibody
titers against PT compared to HUU children: 6 months (43.9 IU/ml [IQR 28.3–71.5] vs.
Fig 1. Specific IgG responses to P. falciparum antigens in HEU and HUU children at different ages. Levels of specific IgG titres were measured against
CSP (1A), PfSE (1B), MSP-3 (1C) and GLURP R0 (1D) in HEU and HUU at three time points, 6 months (during CTX prophylaxis), 12 months (At stopping
CTX prophylaxis) and 18 months (6 months after CTX prophylaxis). X-axis represents age of children in months. Black horizontal bars represent medians.
Black lines represent differences in the median titres between groups at each time point. Blue lines represent a significant change in levels of IgG titres from
baseline in each group. Significant differences are indicated in asterices: Fig. 1A # (p = 0.0401), ## (p = 0.0018), Fig. 1B *(p = 0.038), **(p = 0.0012),
***(p = 0.0097), Fig. 1C # (p = 0.0463), Fig. 1D # (p = 0.0016), ## (p = 0.0007)
doi:10.1371/journal.pone.0121643.g001
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22.4 IU/ml [IQR 4.18–47.4] p = 0.05), 12 months (34.1 IU/ml [IQR 19.3–50.6] vs. 19.6 IU/ml
[IQR 6.48–37.4], p = 0.011) and 18 months (23.9 IU/ml [IQR 14.1–47.4] vs. 16.2 IU/ml [IQR
5.38–31.4] p = 0.029) (Fig. 3B). These results suggest that the difference seen between malaria
antibody responses over time between HEU and HUU are not HIV-mediated but rather reduc-
tion in malaria exposure in the HEU infants due to CTX prophylaxis.
Limited breadth of malaria antibody responses in HEU compared to
HUU infants
The breadth of antibody immune response per serum sample was described as the proportion
of positive serum IgG responses to two or more blood-stage antigens. The proportion of HEU
Fig 2. Specific IgG responses to P. falciparum antigens in HEU and HUU children at different ages. Levels of specific IgG titres were measured against
AMA-1 (2A), MSP-119 (2B), EBA-175RII (2C) and GLURP R2 (2D) in HEU and HUU at three time points, 6 months (during CTX prophylaxis), 12 months (At
stopping CTX prophylaxis) and 18 months (6 months after CTX prophylaxis). X-axis represents age of children in months. Black horizontal bars represent
medians. Black lines represent differences in the median titres between groups at each time point. Blue lines represent a significant change in levels of IgG
titres from baseline in each group. Significant differences are indicated in asterices: Fig. 2A *(p = 0.0059), # (p< 0.0001), ## (p = 0.0015), Fig. 2B *
(p = 0.037), Fig. 2C # (p = 0.0372), Fig. 2D # (p = 0.0107), ## (p = 0.0021).
doi:10.1371/journal.pone.0121643.g002
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children with a positive response was significantly lower compared to HUU children at 6
months (6.45% vs. 33.33%) p = 0.016, but not at 12 (12.0% vs. 32%) p = 0.17 and 18 months of
age (20.7% vs. 23.1%) p = 0.83. However the overall breadth of antibody response during the
Fig 3. Specific IgG responses to Salmonella Typhimurium lipopolysaccharide andBordetella pertussis toxin antigens in HEU and HUU children at
different ages. Levels of specific IgG titres were measured against STM LPS (3A) and PT (3B) in HEU and HUU at three time points, 6 months (during CTX
prophylaxis), 12 months (At stopping CTX prophylaxis) and 18 months (6 months after CTX prophylaxis). X-axis represents age of children in months. Black
horizontal bars represent medians. Black lines represent differences in the median titres between groups at each time point. Blue lines represent a significant
increase in levels of IgG titres from baseline in each group. Significant differences are indicated in asterices: Fig. 3A # (p = 0.0013), ## (p = 0.0263), ###
(p = 0.0038), Fig. 3B *(p = 0.05), ** (p = 0.0108), *** (p = 0.0297)
doi:10.1371/journal.pone.0121643.g003
Table 2. Proportion of HEU and HUU children with positive IgG responses to two or more P. falcipa-
rum blood stage antigens at different ages.
Positive IgG responses to 2 or more antigens
Agea HEU HUU p value c
nb % n %
6d 2 6.45 9 33.3 0.016*
12e 3 12.0 8 32.0 0.17
18f 6 20.7 6 23.1 0.83
Total 11 12.9 23 29.5 0.012*
aAge in Months
b Number of positive responders to two or more antigens
c P value determined by Fisher’s exact test for the comparison of the proportion of positive IgG responses
to two or more antigens
d Number of samples at 6 months of age: HEU (n = 31) and HUU (n = 27)
e Number of samples at 12 months of age: HEU (n = 25) and HUU (n = 25)
f Number of samples at 6 months of age: HEU (n = 29) and HUU (n = 26)
* Statistically signiﬁcant difference at alpha level of 0.05
doi:10.1371/journal.pone.0121643.t002
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entire follow up was significantly lower in HEU children compared to HUU children (12.9%
vs. 29.5%) p = 0.012) (Table 2).
The prevalence of positive IgG antibody responses against AMA-1 and MSP-119 were signif-
icantly reduced in HEU children compared to HUU children: AMA-1 at 6 months (16.1% vs.
51.9%, p = 0.048) and MSP-119 at 12 months (12.0% vs. 44.0% p = 0.025) (Table 3). These re-
sults suggest that exposure to malaria antigens is important in the development of diverse rep-
ertoire of antibody responses against malaria antigens, and this may lead to limited breadth in
malaria antibody responses in HEU infants.
Discussion
We investigated the effect of daily CTX prophylaxis on the acquisition of malaria specific IgG
antibodies during the first year of life in a cohort of HEUMalawian children. IgG antibody re-
sponses against seven blood stage antigens were measured in HEU children during and after
stopping CTX prophylaxis and the responses were compared to aged matched HUU children.
The major strength of this study is that, matching of almost every HEU child to an HUU
child from the same neighborhood meant that both cohorts were likely to be similarly exposed
to malaria despite transmission varying over the course of the follow up period. The results in-
dicate that HEU children on CTX prophylaxis have reduced specific IgG antibody responses to
some malaria blood stage antigens such as recombinant merozoite surface antigens AMA-1,
MSP-119 and whole parasite extract PfSE when compared to HUU children not receiving pro-
phylaxis. IgG antibody responses to the other recombinant blood stage antigens i.e. MSP-3,
EBA-175RII, GLURP R0 and GLURP R2 were not significantly different between HEU and
HUU children during the entire follow up period. However, the study showed that overall
breadth of IgG antibody response to the distinct merozoite antigens is reduced in HEU chil-
dren exposed to CTX prophylaxis. This could be as a result of the delay of acquisition of IgG
antibody responses to PfSE, presumably caused by CTX prophylaxis related reduction in expo-
sure to blood stage P. falciparum infection in HEU children. Ideally, HEU children not on CTX
prophylaxis will have been the better controls in linking CTX prophylaxis and reduced malaria
specific antibodies. Unfortunately recruitment of such a group was declared unethical by the
ethics clearance body.
The use of continuous chemoprophylaxis in children and its effect on development of natu-
ral immunity to malaria has been discussed before [22,23]. In this study, despite evidence of
high exposure to infection in HEU children who had higher IgG antibodies against the sporo-
zoite antigen CSP, IgG antibodies against PfSE in this group were found to be consistently
lower compared to HUU children even after 6 months of stopping CTX prophylaxis. The find-
ings are consistent with a previous report in Senegalese under-five children that showed re-
duced IgG antibody responses against PfSE eight months after receiving a combination of
sulfadoxine-pyrimethamine (SP) and artesunate, a recommended combination primarily used
as malaria prophylaxis [37].
Although the previous study [37] differed with the current study, markedly the preventive
therapy used (IPT with SP + artesunate versus daily CTX prophylaxis) and the age of the chil-
dren (6 weeks—5 years versus 6 months—18 months), the results are in support with the cur-
rent finding that suggests a specific delay in the acquisition of IgG antibodies to total parasite
antigen represented by PfSE in HEU children who had been exposed to CTX prophylaxis and
this effect may persist for several months after stopping the prophylaxis. One possible explana-
tion is that CTX interrupts the cumulative process in the acquisition of antibodies against PfSE
as a result of regular exposure to P. falciparum.
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Low IgG antibody titers to MSP-119were observed in HEU children at 12 months of age.
Previous reports have shown that levels of antibodies to MSP-119 in children depend on pres-
ence and frequent exposure to P. falciparum [12,38,39] and that these antibodies rapidly decay
in the absence of exposure [40]. The results from this study showed that in addition to having
high IgG antibody titers, HUU children had significantly high prevalence of positive IgG anti-
body responses to MSP-119 (44%) compared to HEU children (12%) suggesting a lack of expo-
sure to P. falciparum in the HEU group resulting in delayed acquisition of IgG antibodies to
MSP-119. However, once the protective effect of CTX was removed, HEU children were shown
to rapidly acquire IgG antibodies to MSP-119 suggesting a rapid acquisition of antibodies to
this antigen following exposure to P. falciparum.
The observation that HEU children taking CTX prophylaxis had reduced IgG antibody re-
sponses to AMA-1 compared to HUU children at 6 months of age is consistent with results of
other studies on the reduced antibody production due to lack of exposure. Low levels of IgG re-
sponses to AMA-1 were observed in African adult immigrants with no malaria residing in
Spain for over two years [41] suggesting a negative effect of lack of continuous P. falciparum
exposure on the levels of anti AMA-1 IgG antibodies. Despite the study being different in sev-
eral aspects to the current one, the previous findings support our current observation that lack
of exposure to P. falciparum as controlled by CTX prophylaxis may prevent acquisition of anti-
bodies specific to AMA-1 in these HEU children. However, caution needs to be taken when in-
terpreting this result from the current study since maternally transferred IgG antibodies
against AMA-1 have been shown to persist for up to 12 months whilst gradually declining in
Mozambican children [12]. In addition, we found a significant reduction in the IgG antibodies
to AMA-1 with time in HUU children particular between 6 to 12 months, suggesting a decay
of maternal IgG antibodies in these children. These results and those of another study [12]
seem to suggest that it is possible that at this age, our study measured levels of maternally trans-
ferred anti AMA-1 IgG antibodies instead hence the significant difference observed between
HEU and HUU children. Therefore, because of the potential confounding effect of these mater-
nally transferred antibodies, the true effect of taking CTX on levels of IgG antibody responses
against AMA-1 was difficult to ascertain.
Increasing breadth of IgG antibody specific responses has been shown to be associated with
protection from clinical malaria in children [42,43]. In this study, the breadth of IgG specificity
was used as a marker of cumulative exposure, which can be argued as necessary for develop-
ment of protective immunity to P. falciparum, owing to the fact that children living in endemic
areas are continuously exposed to numerous malaria antigens. We observed that use of CTX
prophylaxis between 6 to 12 months of age was associated with reduced breadth of IgG anti-
bodies in HEU children. However, no evidence of reduced breadth of IgG responses was ob-
served in HEU children after 6 months of stopping CTX prophylaxis. These findings suggest
that CTX may interfere with the exposure of the children’s immunity to a wide range of anti-
gens expressed by the parasite at different stages during an infection.
In uteroHIV exposure has been shown to be associated with lower specific antibody re-
sponses to common infections in HEU children compared with HUU children at birth [44]. To
investigate whether any variation in the levels of IgG antibody responses to the blood stage ma-
laria antigens were either due to CTX prophylaxis or in uteroHIV exposure, IgG antibody re-
sponses to Salmonella Typhimurium lipopolysaccharide (STM LPS) a common infection in
childhood particularly in this region [35,45–47], and EPI vaccine induced responses to Borde-
tella pertussis toxin (PT) were measured in HEU children and compared with HUU children.
We found no evidence of any variation in the levels of specific IgG responses to STMLPS be-
tween HEU and HUU children. Although there have been no previous reports to support this
observation, the current data suggest that reduced placental transfer of antibodies due to HIV
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infection does not result in significantly lower levels of IgG responses to common infection
such as Salmonella Typhimurium in HEU children aged 6 months onwards.
Interestingly HEU children had significantly higher IgG antibody responses to PT com-
pared to HUU children at all ages. These results are consistent with a previous study in South
Africa that showed HEU children to have increased vaccine IgG responses to pertussis com-
pared to HUU children following completion of immunization schedule [44]. A plausible ex-
planation has been suggested in that maternal antibodies mask the vaccine epitopes thereby
preventing recognition of the epitopes by the child’s developing immune system [44,48].
Taken together, these findings suggest that the observed variations in IgG antibody responses
to some of the malaria antigens in HEU children were likely a result of CTX prophylaxis use
rather than as a result of maternal exposure to HIV.
The study was limited in several aspects. Although the study provides clear evidence of the
effect of CTX prophylaxis on the magnitude and breadth of antibody responses, it was however
underpowered to evaluate the risk of clinical malaria in HEU children once the CTX interven-
tion was stopped. Uncertainty remains on whether the so-called protective antibody levels
translate to the functional immunity with responses to the same antigens appearing to be pro-
tective in some studies but not in others [49–53]. Owing to the low numbers of children with
PCR confirmed parasitaemia at the scheduled visits plus the low numbers of malaria episodes,
the study fails to directly determine whether the levels of IgG antibodies to the various antigens
might be associated with protective immunity in these children. Therefore, IgG antibodies to
these blood stage antigens appeared to be mostly markers of exposure rather than protective
immunity to infection.
In conclusion, the present study confirms our hypothesis that use of CTX prophylaxis in the
first year of life interferes with acquisition of natural antibody responses to blood stage malaria
antigens. It has been proposed previously that anti-malaria chemoprophylaxis may interfere
with the natural acquisition of malaria specific immunity. In this study, HEU children on CTX
prophylaxis were shown to have reduced levels of IgG antibodies against AMA-1, MSP-119 and
profoundly against PfSE suggesting that reducing exposure early in life may delay the develop-
ment of natural immunity to malaria. Secondly the breadth of specificity of the antibody re-
sponses against the malaria antigens analyzed was reduced in HEU children taking CTX
prophylaxis. Given that the antibody responses observed in this study were markers of expo-
sure, it remains to be established whether the delay in acquisition of these specific antibody re-
sponses translates into increased risk of malaria infection in HEU exposed to CTX prophylaxis.
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